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Abstract.  Members of the TGF-/~ superfamily appear 
to modulate mesenchymal differentiation,  including the 
processes of cartilage and bone formation.  Nothing is 
yet known about the function of the TGF-#-related 
factor vgr-1,  also called bone morphogenetic protein-6 
(BMP-6), and only limited studies have been con- 
ducted on the most closely related factors BMP-5, os- 
teogenic protein-1  (OP-1) or BMP-7,  and OP-2.  Be- 
cause vgr-1  mRNA has been localized in hypertrophic 
cartilage,  this factor may play a vital role in en- 
dochondral bone formation.  We developed antibodies 
to vgr-1,  and documented that vgr-1 protein was ex- 
pressed in hypertrophic cartilage of mice.  To further 
characterize the role of this protein in bone differentia- 
tion, we generated CHO cells that overexpressed 
recombinant murine vgr-1 protein.  Western blot analy- 
sis documented that recombinant vgr-1 protein was 
secreted into the media and was proteolytically 
processed to yield the mature vgr-1 molecule.  To as- 
sess the biological activity of recombinant vgr-1  in 
vivo, we introduced the vgr-l-expressing  CHO cells 
directly into the subcutaneous tissue of athymic nude 
mice.  CHO-vgr-1 cells produced localized tumors,  and 
the continuous secretion of vgr-1 resulted in tumors 
with a strikingly different gross and histological ap- 
pearance as compared to the parental  CHO cells.  The 
tumors of control CHO cells were hemorrhagic, 
necrotic,  and friable, whereas the CHO-vgr-1 tumors 
were dense, firm,  and fibrotic.  In contrast with control 
CHO tumors,  the nests of CHO-vgr-1 tumor cells were 
surrounded by extensive connective tissue, which con- 
tained large regions of cartilage and bone. Further 
analysis indicated that secretion of vgr-1  from the 
transfected CHO tumor cells induced the surrounding 
host mesenchymal cells to develop along the en- 
dochondral bone pathway.  These findings suggest that 
endogenous vgr-1 acts as an osteoinductive factor dur- 
ing endochondral bone formation. 
U 
RtN6 development,  a variety of growth and differen- 
tiation  factors influence  cell proliferation,  differen- 
tiation,  and  migration.  Several  secreted  peptide 
growth factors have been shown to mediate these processes, 
exerting their activities  locally in an autocrine or paracrine 
fashion  (reviewed  in reference 20).  The TGF-B superfam- 
ily represents one group of such factors that is particularly 
important  in modulating  mesenchymal differentiation  (re- 
viewed in references  10, 41).  This family of factors influ- 
ences pluripotent progenitor cells to differentiate into fibro- 
blasts,  adipocytes, myoblasts,  chondrocytes,  or osteoblasts. 
Correctly coordinated differentiation  of mesenchymal cells 
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into such cell lineages may depend on a defined spatial and 
temporal expression pattern for specific TGF-B-related fac- 
tors (for examples,  see references  14, 31). 
One aspect of mesenchymal differentiation  that remains 
incompletely characterized includes endochondral bone for- 
marion,  bone fracture healing, and ectopic bone formation, 
all of which proceed through  a similar  developmental  cas- 
cade.  In these processes, mesenchymal  precursor cells first 
differentiate  into chondrocytes and give rise to a cartilage 
template.  Within  the center of this  template,  the chondro- 
cytes enter a proliferative  phase, then mitosis arrests and the 
cells  undergo  hypertrophy.  The  hypertrophic  cartilage 
mineralizes  in the later stages of maturation,  and is eventu- 
ally invaded by blood vessels and replaced by a mineralized 
bone matrix.  This bone matrix  is deposited by osteoblasts, 
which also have differentiated from mesenchymal progenitor 
cells. Recent evidence implicates  TGF-~ superfamily  mem- 
bers as playing a central  role in this complex developmental 
process (reviewed in references  10, 55). 
The TGF-B superfamily  consists of a growing number of 
homologous, secreted, disulfide-bonded dimers (reviewed in 
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into several groups, based on sequence homology.  One of 
these groups consists of the three "I'GF-/3 isoforms,  TGF-/31, 
-/Y2, and -/~3. Other distinct groups include the activins,  in- 
hibins, and Mtillerian inhibitory substance. However, by far 
the largest  group comprises the bone morphogenetic pro- 
teins  (BMPs)  ~, Xenopus vg-1, Drosophila decapentaplegic 
(dpp), and the more recently cloned polypeptides nodal (59), 
dorsalin (3), vgr-2  (22), and growth/differentiation  factors 
(GDF)-I (27) and GDF-3 (33). This group has been referred 
to as the decapentaplegic/vg-l-related proteins (DVR) (30). 
The TGF-~  superfamily,  and especially the DVR group, 
appears to be of considerable importance in bone and carti- 
lage development.  Several members of this superfamily have 
been localized during  intramembranous and endochondral 
bone formation,  and they are expressed in a spatially  and 
temporally distinct  but overlapping  pattern in the differen- 
flating tissue (for an example, see reference 31). The proteins 
that have been best characterized in terms of their osteoin- 
ductive activity are the subgroup consisting  of BMP-2 and 
BMP-4 (reviewed in reference 55), which bear closest ho- 
mology with the decapentaplegic complex protein dpp of 
Drosophila (38).  BMP-2 and BMP-4 have the ability to in- 
duce osteoblastic differentiation  in vitro and ectopic bone 
formation when injected intramuscularly  (for examples,  see 
references 6, 17, 18, 24, 49, 51, 56, 57), and are at least par- 
tially responsible for the osteoinductive activity originally 
purified from bone (40, 46). 
The largest subgroup of DVR proteins consists of BMP-5 
(5),  vgr-1 (29) or BMP-6 (5),  osteogenic protein-1  (OP-1) 
(36) or BMP-7 (5), and OP-2 (37), all of which have a high 
degree of homology to the ancestral 60A protein in Drosoph- 
i/a (12). Although BMP-7 has been shown in an initial study 
to induce bone formation  in vivo (43) and osteoblastic and 
chondrocytic differentiation in vitro (1, 43), little is currently 
known about the functions of the other members of this sub- 
group and their expression patterns during  mammalian  de- 
velopment. To define the function of this subgroup in mesen- 
chymal differentiation  and especially during  endochondral 
bone formation, we have selected vgr-l/BMP-6  as a proto- 
type for our studies. This eDNA was originally isolated from 
a murine embryonic eDNA library and was named vgr-l, 
based on its homology with Xenopus vg-1 (29).  The human 
and bovine homologues of vgr-1 were subsequently cloned 
from bone and were named BMP-6 (5), but no bone mor- 
phogenetic activity has been reported for this protein.  Exten- 
sive  in  situ  hybridization  analyses  have  localized  vgr-1 
mRNA expression to the central nervous system, to various 
epithelial  structures  including  the suprabasal  layer  of the 
epidermis, and, of most relevance to the current studies,  to 
hypertrophic cartilage (21, 31). Notably, it is the only mem- 
ber of the TGF-B superfamily  that has been localized to 
hypertrophic cartilage,  and, as such, vgr-1 protein could be 
involved in the maturation of hypertrophic cartilage  and/or 
stimulation  of osteoblastic differentiation.  However, in a re- 
cent immunohistochemical localization  study, vgr-1 protein 
was not detected in hypertrophic  cartilage,  suggesting that 
there may be translational  inhibition  of vgr-1 expression  in 
the latter tissue (50). 
1. Abbreviations used in this paper: BMPs, bone morphogenic proteins; 
dhfr, dihydrofolate reductase; dpp, decapentaplegic; DVR, dpp/vg-l-related 
proteins; GDF,  growth/differentiation  factors; OP-1, osteogenic protein-l. 
In this study, we developed antibodies to vgr-1, and showed 
that vgr-1 protein was indeed expressed in hypertrophic carti- 
lage. Furthermore, we generated transfected CHO cells that 
produced recombinant vgr-1 protein,  and showed that  the 
protein was proteolytically processed and secreted by these 
cells.  Injection  of the vgr-l-expressing CHO cells into the 
subcutaneous tissue of nude mice resulted in tumors with 
fibrosis and regions of cartilage  and bone. Further analysis 
indicated  that vgr-1 secreted by the injected CHO cells in- 
duced the surrounding  host mesencbymal cells to differenti- 
ate into chondrocytes and osteoblasts.  Our data indicate that 
vgr-1 may represent a vital factor for differentiation along the 
endochondral bone cascade. 
Materials and Methods 
Construction of the ~,r-I Expression Vector 
To obtain the vgr-I gene, a 780-bp SmaI fragment from the 5' end of the 
vgr-I eDNA was used as a probe to screen a mouse genomic library in h 
Charon 4A  under  high stringency.  The  library  was  plated  at  50000 
pfu/plate,  and '~1  x  10  ~ clones were screened. Candidate positive clones 
from  duplicate  filter lifts were  purified through subsequent rounds of 
screening.  Library plating, probe labeling, phage lifts, and filter hybridiza- 
tions were carried out as described previously (11). Restriction fragments 
of one such phage were suboloned into pUC219 for further mapping,  and 
subsequently sequenced in M13 through standard dideoxy sequencing (44) 
with Sequenase  (United States Biochemical Corp., Cleveland, OH). This 
analysis led to the identification  of the first coding exon of the vgr-1 gene. 
For expression studies, the original vgr-1 eDNA (29) was suboloned into 
the BamHI-EcoRI site of the pRK7 expression vector (53). To generate the 
composite full-length vgr-1 eDNA expression vector, we replaced the 5' 
coding sequence of the original eDNA (29) with an 851-bp BamHI/BspHI 
genomic fragment that contained 5' flanldn~ DNA and the first coding exon, 
and then performed a three-part ligation in which this fragment was ligated 
with the downstream 1551-bp BspHI/EcoRI 3' vgr-1 eDNA fragment and 
the pRK 7 expression vector that had been digested with BamHI and EcoRI. 
The resultant plasmid was named pRK7-vgr-1. 
Cell Culture and Transfection 
CHO cells deficient in the synthesis of dihydrofolate rednctase (dhfr) (47) 
were propagated  in F-12 Ham's nutrient mix (Gibco BRL, Gaithersbuvg, 
MD) and supplemented with 10% fetal calf serum (Hyclone Laboratories, 
Logan, UT), 100 U/ml penicillin, and 100 #g/ml streptomycin  (both from 
Giboo BRL). Cells were tmmfeoed with 15 t~g of the pRK7-vgr-1 expres- 
sion vector and 300 ng of pSV-dhfr DNA (45) using the calcium-phosphate 
precipitation method (52).  Cells were incubated for 4 h, the medium was 
removed,  and the cells were exposed to a  15% glycerol  shock for 1 min. 
After rinsing twice with PBS, the cells were incubated in supplemented me- 
dia until they reached confluence,  at which time they were split 1:8 and 
selected in media lacking glycine,  hypoxanthine,  and thymidine, and sup- 
plemented with 5  %  dialyzed  fetal calf serum.  Individual clones were 
selected after 3 wk, and, after expansion, were screened by Northern blot 
analysis for expression of vgr-1 mRNA. The integrated plasmid sequences 
of several positive clones were amplified through culturing in gradually in- 
creasing levels of  methotrexate,  up to 500 nM, thereby generating the CHO- 
vgr-1 cells. 
Transient transfections of pRK7-vgr-1 into 293 cells were performed as 
described previously (15). 
RNA Preparation and Northern Blot Analysis 
Total  RNA was prepared from cultured cells by lysis  with guanidinium 
isothiocyanate,  phenol extraction, and ethanol precipitation, according to 
standard protocols (7). The RNA was quantitated spectrophotometrically 
at 260 nm, and was stored at -70°C until use. For Northern blot analysis, 
20/~g of total RNA was electrophoresed in a formaldehyde  gel in MOPS 
buffer and transferred to nylon membranes (Gene Screen; New England 
Nuclear, Boston, MA). The vgr-1 eDNA probe corresponded to the 2.4-kb 
BamHI/EcoRI eDNA from the pRK7-vgr plasmid, and was radiolabeled 
using the [32P]dCTP random primer labeling method (Oligolabeling  Kit; 
The Journal of Cell Biology, Volume 126, 1994  1596 Pharmacia, Uppsala, Sweden).  Hybridization, washing, and autoradiogra- 
phy were performed as described previously (14). 
Cell Growth Rate 
CHO or transfected CHO-vgr-1 cells were rinsed with PBS, trypsinized in 
0.25% trypsin with 0.02% versene, and diluted in standard media. The cell 
number was determined using a Coulter counter (Coulter Corp., Hialeah, 
FL), and 10,000 cells were plated per well on 24-well plates. The cells were 
grown in standard media with 10% fetal calf serum. FOr analysis of growth 
rate in the presence of serum, the wells  were rinsed, trypsinized, and 
counted at regular intervals starting 12 h after initial plating. For each time 
point, three separate wells of cells were individually counted three times, 
and the cell number was then averaged.  FOr analysis of growth rate in the 
absence of sernm, the freshly plated cells were grown in 10% fetal calf se- 
rum for 24 h, then the cells were rinsed three times with PBS and subse- 
quently  grown  in  media  supplemented  with  insulin,  transferrin,  and 
selenium (GMS-G supplement; Gibco-BRL). The cells were again grown 
in triplicate for each time point, and were first counted 24 h after the serum 
had been withdrawn. 
Antibody Production 
Oligopeptides were synthesized corresponding to the deduced murine pro- 
tein sequence at amino acids  141-157 for the pro region antibody and 
392-407 for the mature region antibody (see Fig. 2). No similar sequences 
are present in BMP-5 and BMP-7, and therefore no crossreactivity was ex- 
pected between the vgrol antibodies and these BMPs. An additional cysteine 
residue was added to the amino terminus of each oligopeptide.  The peptides 
were coupled to keyhole limpet hemocyanin according to the method of 
Green et al. (16), and were then mixed in Freund's adjuvant and injected 
into rabbits (Caltag Laboratories, Inc., South San Francisco, CA).  Two 
animals were injected with each antigen. The initial injection consisted of 
150/tg in Freund's adjuvant with subsequent booster doses of 100/tg 3 and 
4' wk from the initial injection. The first bleed occurred at 5 wk from the 
initial injection. A 100-~g injection was given after that bleed, and follow- 
up bleeds and injections were each performed at weekly intervals for the 
next 2 wk, and with a last bleed 1 wk later. There was a 2-wk rest period, 
then weekly  booster injections for 2 wk,  followed by a repetition of the 
above cycle.  Antisera was stored at -20°C until use. 
Whole antisera was used for Western blot analysis at the dilutions noted 
below. FOr immunohistochemistry, the antisem were first purified by pas- 
sage over the appropriate antigen affinity column. The columns were con- 
structed by coupling of the synthetic oligepeptides to Affigel-10 (Bio Red, 
Laboratories, Richmond, CA) according to manufacturer's instructions. 
The antisera was purified by mixing with an equal volume of 0.1 M PBS 
(pH 7.2) and loading onto the appropriate affinity column that had been 
preequilibrated with this buffer. The column was washed with PBS until the 
eluant achieved a baseline reading at OD2som. The specific anti-vgr-1 anti- 
bodies were then eluted with 40 mM diethylamine (pH 11.4), and exchanged 
into PBS buffer by passage over a  YM-10  membrane (Amicon Corp., 
Beverly, MA). 
Western Blot Analysis 
Conditioned media was collected from CHO or CHO-vgr-1 transfectants 
grown in media in the absence of serum for 24 h. 200-~1 aliquots were 
lyophilized to dryness, and were resusponded in sample buffer under reduc- 
ing conditions with 5 %/~-mercaptoethanol. After SDS-PAGE, the samples 
were Uunsferred to nitrocellulose.  Immunoblotting was performed with the 
enhanced chemiluminesence kit (Amersham Corp., Arlington Heights, IL) 
according to  manufacturer's recommendations. Whole antisera directed 
against the precursor oligopeptide  were used at a 1:1000 dilution, and that 
derived from the mature oligopeptide was used at a 1:250 dilution. Incuba- 
tions with the antibodies were performed overnight at 4°C. 
Injections into Nude Mice 
Homozygous  nude, athymic 30-g female mice were obtained from Charles 
River Laboratories (Wilmington, MA). 5  ×  106 CHO or CHO-vgr-1 cells 
were injected into the right paraspinous area in the lower lumbar region. 
Cells were prepared for injection by trypsinization, multiple washes with 
PBS,  and resuspension in 0.5  ml of serum-free media per sample.  The 
animals were fed ad libitum and monitored three times per week for the ap- 
pearance of solid tumors. When the tumors reached 4  cm in largest di- 
ameter, or by 4  wk, the animals were euthanized, and the tumors were 
resected.  Portions of the tumors were fixed in 4% paraformaldehyde  and 
embedded in paraffin. The remainder were placed in Tissue Tek OCT com- 
pound (Miles Inc., Elkhart, IN) and snap frozen in liquid N2. 
Histochemistry and Immunohistochemistry 
5-/an paraffin sections were used for all histocbemical analyses,  and all 
staining was performed according to standard procedures (8). 
For immunocytochemistry,  cells were grown on tissue culture chamber 
slides (Nunc Inc., Naperville, IL) to 80% confluence,  washed with PBS, 
fixed in methanol for 10 min, and then stored at -70°C. After several PBS 
rinses, endogenous peroxidase activity was quenched with 0.3%  H202 in 
10% methanol for 20 min. The slides were again rimed in PBS and blocked 
with 3 % BSA in PBS for 30 min at room temperature. The primary antibod- 
ies were then applied and incubated overnight at 4°C. The affinity-purified 
vgr-1 precursor antibody was used at a 1:50 dilution (8/~g/mi). After washes 
with PBS-0.1% Tween 20, anti-rabbit IgG horseradish peroxidase (Amer- 
sham Corp.) was applied at a 1:1000 dilution for 60 rain at room tempera- 
ture.  After  further  washes,  3-amino-9-ethylcarbazole (AEC)  substrate 
(Dako Co., Carpinteria, CA) was added for 5 to 10 minutes, and then the 
slides were washed in de-ionized H20, counterstalned with bematexylin, 
and washed with tap H20. 
For analysis of vgT-1 expression in histological sections, we collected 
mice from gestational day  18.5 embryos, fixed the tissue in 4% parafor- 
maldehyde for 30 minutes, and used 5 ~m sections for immunostaining. The 
afffiulty-purified  mature vgr-I antibody was used at a 1:50 dilution (6 ~g/ml). 
FOr analysis of the tumors, we used sections from tumors that had been snap 
frozen in liquid N2 following embedding in Tissue Tek OCT Compound. 
The collagen type I antibody was an affinity purified goat antibody raised 
against human and bovine antigens,  and the collagen type II antibody was 
an afffiulty-purified antibody directed against the bovine antigen (both anti- 
bodies  from  Southern Biotechnulogies,  Inc.,  Birmingham, AL).  Both 
antibodies were used at dilutions of 1:1,500. The monoclonal routine os- 
teocalcin antibody was  purchased  from Biomedical  Technologies,  Inc. 
(Stoughton, MA), and was used at a  1:200 dilution. 
In Situ Hybridization 
To evaluate the expression of dihydrofolate reductase, we used the 548-bp 
BamHI/BgilI fragment from the 3' untranslated region of  the hepatitis B sur- 
face antigen gene, which had been incorporated into the 3' region of the di- 
hydrofolate reductase expression unit (45).  This fragment was cloned into 
the Bluescript vector (Stratagene, La Jolla, CA), and sense and antisense 
riboprobes were generated with [35S]UTP and T3 and T7 RNA polymer- 
ases, respectively,  according to the suppliers protocols (Promnga Corp., 
Madison, WI). 
Frozen sections of 5 pm were cut onto "probe-un plus" microscope slides 
(Fisher Scientific, Pittsburgh, PA), and stored at -70°C. The sections were 
fixed in paraformaldehyde,  acetylated, and prehybridized essentially as de- 
scribed previously (34). Prehybridization  was performed at 50°C in hybrid- 
ization buffer for 1 h, and then the solution was removed and replaced with 
the same buffer containing 1 ×  106 cpm of riboprobe, and incubated for 
16 h at 50°C. Posthybridization  washes and RNase treatments were carried 
out as noted previously (34).  After washes,  the slides were dehydrated  in 
increasing concentrations of ethanol with 0.3  M  ammonium acetate, air 
dried, and dipped into Ilford Nuclear Research Emulsion (Cheshire, United 
Kingdom).  Sections were exposed in fight safe boxes at 4°C for 6 d, and 
then developed  in D-19 developer (Eastman Kodak,  Rochester,  NY). The 
slides were counterstained in Harris' hematoxylin, and then analyzed under 
bright-field  and dark-field  microscopy. 
Results 
Vgr-1 Protein is Expressed in Hypertrophic Cartilage 
Previous in sire hybrid  iTCtion studies have documented ex- 
pression of vgr-1 mRNA in the central nervous system, vari- 
ous epithelial  structures including  the suprabasal layer of 
skin, and hypertrophic cartilage (21, 31). Wall et al. recently 
developed an antibody directed against the precursor region 
of  the  murine  vgr-1 protein,  and  subsequent  immuno- 
histochemical  analysis in the developing  mouse confirmed 
the presence  of vgr-1 protein in the central nervous system 
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body failed to detect vgr-1 protein expression in hypertrophic 
cartilage  and in some cell lines that express vgr-1 mRNA, 
suggesting  that there was translational  control of vgr-1 ex- 
pression. Thus, before proceeding with our studies  on the 
role of vgr-1 in endochondral bone formation,  we had to de- 
termine if  vgr-1 protein was even present in hypertrophic car- 
tilage. Towards this end, we developed polyelonal antibodies 
that specifically  recognized both the precursor and mature 
portions of the murine vgr-1 protein. 
No purified  vgr-1 protein was yet available  for antibody 
production. Instead,  we synthesized two oligopeptides from 
the deduced murine vgr-1 cDNA sequence for use as im- 
munogens.  These peptides were selected from regions that 
have no similarity  with the corresponding sequences of the 
most closely related factors BMP-5 and -7 (5), and thus the 
resultant  antibodies  should not cross-react with any related 
DVR-like  factor.  Oligopeptides  corresponding  to  amino 
acids 141-157 in the precursor and 392-407  in the mature 
portion of the vgr-1 protein (see Fig. 2) were synthesized, 
coupled to keyhole limpet hemocyanin,  and were then used 
as immunogens  in rabbits.  Antisera exhibited high titers in 
ELISA assays with these peptides,  and reacted in Western 
blot assays with recombinant vgr-1 protein synthesized  by 
transfected CHO ceils (see below). The whole antisera were 
then  affinity  purified using the appropriate  immunogenic 
oligopeptide coupled to Affigel as an affinity matrix,  and 
they yielded antibodies suitable for immunohistochemical 
analyses of vgr-1 expression. 
Immunostaining  using the antibody raised against the ma- 
ture,  carboxy-terminal  portion of the protein detected vgr-1 
protein in the suprabasal  layer of the epidermis (see Fig.  1, 
A and B), as described previously (50).  In addition,  and of 
importance to our study, we detected vgr-1 protein in hyper- 
trophic cartilage  (Fig.  1, A and C). This staining  was pre- 
dominantly  in  the  extracellular  matrix  surrounding  the 
hypertrophic  chondroeytes.  Furthermore,  vgr-1 protein lo- 
calized specifically to regions of hypertrophic  cartilage  that 
had undergone  mineralization,  as shown by corresponding 
von Kossa staining in an adjacent tissue section (Fig.  1 D). 
Thus,  vgr-1 protein appeared in the latter stages of hyper- 
trophic cartilage  differentiation.  The negative control, per- 
formed with substitution  of rabbit IgG as the primary anti- 
body, resulted in no such staining pattern, demonstrating  the 
specificity of the vgr-1 immunostaining.  When using the an- 
tibody raised against the precursor segment peptide, vgr-1 
protein was again detected in skin, but only ,~ery weak im- 
munostaining  was apparent in hypertrophic cartilage  (data 
not shown). 
Expression of  Recombinant Vgr-1 Protein by 
Tmnsfected Cells 
The expression of vgr-1 in the hypertrophic cartilage  sug- 
gested that it may play a role in the maturation  of the hyper- 
trophic ehondroeytes and/or may stimulate new bone forma- 
tion.  However, to date, ,no natural  vgr-1 protein has been 
purified,  and thus nothing  is known about its physiological 
activities.  Therefore,  to determine the role of this factor in 
endoehondral bone formation,  it was necessary to first pro- 
duce recombinant vgr-I  protein. 
Initially,  the  published  vgr-1 eDNA  (29)  was  inserted 
downstream of the cytomegalovirus promoter in the expres- 
sion vector pRK7. However, transfections  of this expression 
vector into 293 cells did not result in detectable vgr-1 protein 
expression.  Inspection of the predicted vgr-1 polypeptide se- 
quence  showed  that  the  NH2-terminal  sequence  did  not 
comply well with the consensus rules of von Heijne for sig- 
nal peptides (48),  and we suspected that our eDNA clone 
was  partial  length.  We  subsequently  screened  a  murine 
genomic library with a 5' vgr-1 eDNA probe, and identified 
an upstream exon that contained the 5' untranslated  region, 
a translational  initiation consensus sequence (26), and a ca- 
nonical  signal peptide sequence (48).  Primer extension  ex- 
periments,  using RNA from PYS cells, verified that this se- 
quence represented the 5' end of the vgr-1 mRNA (Kobrin, 
M. S., unpublished data). Furthermore, the polypeptide se- 
quence deduced from this genomic fragment now had a high 
degree of sequence similarity  with the NH2 terminus  of bo- 
vine BMP-6 (5). In retrospect, we believe that the different 
5' end in the published mouse vgr-1 sequence (29) resulted 
from a eDNA artifact that is likely related to the high G-C 
content of this sequence.  We then constructed a composite 
vgr-1  expression  vector in  pRK7 by ligating  a  5'  851-bp 
BamHI-BspHI genomic  fragment onto the corresponding 
downstream vgr-1 eDNA fragment (29). Transient transfec- 
tions of the pRK7-vgr-1 plasmid into 293 cells and metabolic 
labeling of the proteins now resulted in the appearance of an 
overexpressed protein consistent in size with the vgr-1 pro- 
tein (data not shown).  The full-length  cDNA sequence en- 
coding  the  510-amino  acid  murine  vgr-1 polypeptide is 
shown in Fig.  2. 
To produce a stable source of recombinant vgr-I protein, 
we cotransfected  pRK7-vgr-1 and a dihydrofolate reduetase 
expression plasmid into CHO ceils,  selected several clones 
expressing high levels of vgr-1 mRNA, and amplified its ex- 
pression  in  the  presence  of increasing  concentrations  of 
methotrexate.  As shown in Fig. 3 A, Northern blot analysis 
revealed a high level of vgr-1 mRNA in one such clone grown 
in 500 nM methotrexate.  In contrast, CHO cells transfected 
with dihydrofolate  reductase  alone  did  not express  vgr-1 
mRNA.  Immunostaining  using  the  vgr-1 antiserum  also 
showed specific staining of the vgr-1 mRNA-overproducing 
CHO-vgr-1 cells,  indicating  the synthesis  of vgr-1 protein 
(Fig. 3 C). The parental CHO cells exhibited no such stain- 
ing,  again indicating  lack of vgr-1 expression. 
To assume biological  activity, members of the TGF-B su- 
perfamily must enter the secretory pathway and undergo a 
proteolytic cleavage that separates the precursor region from 
the biologically active carboxy terminal  domain.  To deter- 
mine  if such processing  occurs  in  the  CHO-vgr-1  stable 
transfectants,  we collected conditioned  media produced by 
these cells and performed Western  blot analyses using  our 
vgr-1 antisera (Fig. 3 B). After denaturing  gel electrophore- 
sis under reducing conditions and Western analysis, each an- 
tiserum recognized two protein bands from the media of 
transfected  cells,  but not of the nontransfected  cells.  The 
larger protein band had a size of "~69 kD, and it reacted in 
Western blots with antisera raised against both the precursor 
and  mature  vgr-1 segments.  This  band  most  likely  cor- 
responded to  the  uncleared  vgr-1 precursor  polypeptide, 
given its dual antibody reactivity and its size. Two lower pro- 
tein bands were seen as well: a 46-kD protein that reacted 
only with the antibody specific for the vgr-1 precursor seg- 
ment, and a 23-kD protein that reacted with the antibody for 
mature vgr-1. These proteins thus corresponded to the two 
The Journal of Cell Biology, Volume 126,  1994  1598 Figure L  Vgr-1 protein expression in skin and hypertrophic cartilage. Forelimbs from 18.5-d gestation mice were stained with affinity- 
purified antibody directed against the mature portion of  vgr-1. (A) xl0 view showing  vgr-1 expression in both suprabasal layer of  epithelium 
(arrows) and hypertrophic cartilage (center offigure). Bar, 200/zm (B) x20 view of the skin showing localization of vgr-1 to suprabasal 
layer of epithelium. (C)  x20 view of vgr-1 expression in hypertrophic cartilage (center). (D) Section adjacent to that used for C, with 
von Kossa stain (black) indicating  areas of  mineralization, and counterstained with nuclear fast red. (E) Negative  control, where nonspecific 
IgG is used as the primary antibody. 
cleavage products expected after proteolytic processing of 
the vgr-1 precursor. These cells secreted ~2 #g/ml per 24 h 
of the recombinant factor, and based on these Western anal- 
yses, ,x,50% of the secreted protein had been proteolytically 
processed. The 69- and 46-kD bands each migrated as a sub- 
tie doublet (Fig. 3 B), which was most apparent in lower per- 
centage polyacrylamide gels  (data  not shown).  This may 
have been caused by variations in glycosylation. 
Effects of vgr-1 on CHO Cells in Culture 
To  determine the effect of vgr-1 overexpression on these 
cells, we characterized changes in morphology, growth rate, 
and collagen synthesis. No significant difference in cell size, 
shape, or adherence was noted between CHO and CHO-vgr-1 
cells (Fig. 3 C). However,  in comparison with the parental 
CHO cells, CHO-vgr-1  cells had a significantly slower rate 
Gitelman et al.  Vgr-I Induces Endochondral Bone Formation In  Vivo  1599 1:  gat cctggcggtogcggcgtcgt  ct ct tctccacccgggct  tetgggccacccgcggatgaccat  gagagataaggact  gagtgccagaa 
91:  aagggaagagagcccgcagagaggt  ggcgggggct  gcacactccgagggaacagcat~agagatccggcct  agct cogccgctcgaagac 
181:  tag  a ggg o c co gc gg gg ga agcc gggc t  g ggaggQ g&fI~)CCCG~..,GCTGG~IGC~gtGG(X~IkGrI"~GCrI~C3rI~I.C~~~O 
i:  M  P  G  L  G  R  R  A  Q  W  L  C  W  W  W  O  L  L 
271"  TGCAGCTGCGGCCCCCCGCCACTGCGGCCCCCTCTGC CGGTAGCCGCGGCCGCCGCCGGGG~~~C~~CC  G 
19"  C  S  C  G  P  P  P  L  R  P  P  L  P  V  A  A  A  A  A  GVG  Q  L  L  G  A  G  G  S  P 
361:  GTGCGCGCTGAGCAGCCACCGCCACAGTCCTCTTCTTCGGGCTTCCTCTATCGGCGGCTCAAGACCCAC GAGAAGCGGGAGATGCAAAAG 
49:  V  R  A  E  Q  P  P  P  Q  S  S  S  S  G  P  L  Y  R  R  L  K  T  H  E  K  R  E  M  Q  K 
451:  GAGATCCTGTCGGTGCTGGGGCTCCCGCACAGGCC GCGGCCCCTGCACGGTCTCCAGCAGCCTCA~CCCC~CCCGC~G~G 
79:  E  I  L  S  V  L  G  L  P  H  R  P  R  P  L  H  G  L  Q  Q  P  Q  P  P  V  L  P  P  Q  Q 
541:  CAGCAGCAGCAGCAGCAGCAGCAGACGGCCCGC GAGGAGCC  CCCTCCAGGGCGGCTGAAGTCCGCTCCACTCTTCATGCTGGA~TAC 
109"  Q  Q  Q  Q  Q  Q  Q  0  T  A  R  E  E  P  P  P  G  R  L  K  S  A  P  L  F  M  L  D  L  Y 
631"  AACGCCCTGTCCAATGACGACGAAGAGGATGGGGCATCGGAGGGTGTGGGGCAAGAGCCTGGGTCCCAC GGAGGGGC~TC~CC~G 
139:  N  A  IL  S  N  D  D  E  E  D  G  A  S  E  G  V  G  Q  E [P  G  S  H  G  G  A  S  S  S  Q 
721,  CTCAGGcAGCCGTCTCCCGGCGCTGCACACTCCTTGAACCGCAAGAGTCTCCTGGCCCCGGGACCCGGTGG~GGTGCGT~c~C~AcT 
m  I 
169"  L  R  Q  P  S  P  G  A  A  H  S  L  N  R  K  S  L  L  A  P  G  P  G  G  G  A  S  P  L  T 
811:  AGCGCGCAGGACAGCGCTTTC  CTCAAC  GACGCGGACATGGTCATGAGCTTTGTGAACCTGGTGGAGTACGACAAG~TCCC~T 
199:  S  A  Q  D  S  A  F  L  N  D  A  D  M  V  M  S  F  V  N  L  V  E  Y  D  K  E  F  S  P  H 
901,  CAACGACACCACAAAGAGTTCAAGTTCAACCTATcCCAGATTCcTGAGGGTGAGGCGGTGACGGCTGCTGAGTTCCGCGT•TACAAGGAC 
229:  Q  R  H  H  K  E  F  K  F  N  L  S  Q  I  P  E  G  E  A  V  T  A  A  E  F  R  V  Y  K  D 
991  : TGTGTGGTGGGGAGTTTTAAAAAcCAAACCTTTCTTATCAGCATTTAcCAAGTCTTGCAGGAGCATCAGCACAGAGA~CCTA~T 
259:  C  V  V  G  S  F  K  N  Q  T  P  L  I  S  I  Y  Q  V  L  Q  E  H  Q  H  R  D  S  D  L  F 
1081  : TTGTTGGACACCCGGGTGGTGTGGGCCTCAGAAGAAGGTTGGCTGGAATTTGACATCACAGCAACTA~~~~CCG 
289:  L  L  D  T  R  V  V  W  A  S  E  E  G  W  L  E  P  D  I  T  A  T  S  N  L  W  V  V  T  P 
1171,  CAGCACAACATGGGGCTCCAGCTGAGTGTGGTGACTCGGGATGGACTCCACGTCAACCcCCGTGCGGCGGGCCTGGTGGGCAGAGACGGC 
319:  Q  H  N  M  G  L  Q  L  S  V  V  T  R  D  G  L  H  V  N  P  R  A  A  G  L  V  G  R  D  G 
1261,  CCTTACGACAAGCAGCCCTTCATGGTGGCCTTCTTCAAGGTGAGCGAGGTCCACGTGCGCACCAC CAGGTCAGCCTCCAGTCGGC  GGCGG 
349"  P  Y  D  K  Q  P  F  M  V  A  F  F  K  V  S  E  V  H  V  R  T  T  R  S  A  S  S  R  R  RV 
1351:  CAGCAGAGTCGCAACCGGTCCAC  CCAGTCGCAGGACGTGTCCCGGGGCTCCGGTTCTTCAGACTACAACGGCAGTGAGTTAAAAA~T 
379,  Q  Q  S  R  N  a  S  T  Q  S  Q  D  VI S  R  G  S  G  S  S  D  Y  N  G  s  E  L  K  T [A 
1441-  TOC~Oa~OC~TO~'GC~C~TOTO~OC~CCXOOaCCTOOOATOOCAOOACTOO~~CC~~C~C~C~ 
409:  C  K  K  H  E  L  Y  V  S  F  0  D  L  O  W  Q  D  W  I  I  A  P  K  O  Y  A  A  N  Y  C 
1531,  GATGGAGAGTGTTCCTTCC  CACTCAACGCACACATGAATGC  CACCAACCAC  GCCATTGTACAGACCTTGGTCCACCTTATGAATCCCGAG 
439"  D  G  E  C  S  F  P  L  N  A  H  M  N  A  T  N  H  A  I  V  Q  T  L  V  H  L  M  N  P  E 
1621:  TAC  GTCCCCAAAC  CATGCTGC  GCACCAACCAAACTGAAT  GC  CATCTCGGTTCTTTACTTCGATGATAACTCCAATGTCATCTTGAAAAAG 
469:  Y  V  P  K  P  C  C  A  P  T  K  L  N  A  I  S  V  L  Y  P  D  D  N  S  N  V  I  L  K  K 
1711  :  TACAGGAATATGGTCGTGAGAG~TTGTGGTTGCCATTAAgttgaagctggtgtgtgtgtgtgggtgggggcatggttctgccttggattc 
499:  Y  R  N  M  V  V  R  A  C  G  C  H  * 
1801:  ctaacaacaacat  ct  gcct  taaaccacgaacaacagcacagcgaagcgggatggt gacacacagagggat  cgt  gacacgcagacacatct 
1891:  ~g~tggtg~tta~c~a~ggagg~ttttatgagga~cttgt~aaggg~ttt~ccagttcctaactgagcagttgctggtctgcaggaa 
1981-  gctggaaggct  tgtagt  ac  aggcct  ggaaactgcagt  tacctaat  gttcgcct  cccccaaccccgcccggagtagt  t  tt  agct  tt  tagat 
2071:  ctag~tgcttgtggtgtaagtaaa~ttgaaggaatattaaatat~tgggttgaaagacccggtggtgg~tc~acag~a~atcccag 
2161,  ggagatttttgcagacatccgaatggaggggagaagggcactcttt¢aggttc~attcccagcaagggcagctcacaca~gacctgcagc 
2251-  ctggccatcagcaggctctgtggaggtgccttctgtctactgttgtagttacgtgttttgtgttgactctcggtggtgtgagaatgtact 
2341-  aatctctgtcaagacaaactgtagcatttccaccccatcctcctccctccctcacagaattc 
Figure 2. Nucleotide and deduced amino acid sequence of composite vgr-1 eDNA. The 5' 851 bp are derived from a BamHI/BspHI  genomic 
fragment,  and the downstream  1551 bp are from previous vgr-1 eDNA cloning (29). Nueleotide and amino acid numbering is shown in 
the left column.  Untranslated nueleotides are in lowercase lettering. Oligopeptides used for antibody production are boxed, and potential 
N-linked glycosylation sites are underlined.  Potential cleavage sites for eliminating the signal sequence (48) and for separating precursor 
from mature domains are marked with inverted arrowheads. The stop codon is marked with an asterisk. The nueleotide and protein sequence 
data reported  in this paper will appear in the EMBL Database under the accession number X80992. 
of cell proliferation both in the presence and absence of se-  example, see reference 13),  and we reasoned that the con- 
rum (Fig. 4). There were no differences in levels of expres-  tinuous  release  of recombinant  vgr-1  by the  tumor  cells 
sion of collagen I and II, as assessed by immunocytochemis-  would allow us to evaluate the biological activity of vgr-1 in 
try and Northern blot analysis (data not shown),  vivo. This approach would thus not necessitate the purifica- 
tion of recombinant vgr-1, but would rely on a continuous re- 
Vgr-l-expressing  ClIO Cells form Tumors with  lease of vgr-1 that was naturally activated and incorporated 
Altered Phenotype  into the extracellular matrix. To this end, we injected CHO 
To evaluate the effects of vgrA in vivo, we injected the vgr-  or CHO-vgr-1 cells into the fight paraspinous area in the 
1-expressing  CHO  cells  subcutaneously  into  nude  mice.  lower lumbar region of nude,  athymic mice. Five animals 
Previous studies had shown that CHO cells form localized  were injected with the parental cells, and five with the stable 
tumors when injected subcutaneously into nude mice (for an  transfected CHO-vgr-1 cells.  One animal from each group 
The Journal of Cell Biology, Volume 126, 1994  1600 Figure 3.  Characterization of CHO- 
vgr-1 stable transfectants. (A) North- 
ern blot analysis of total RNA from 
CHO (lane 1) and CHO-vgr-1 cells 
(lane 2) after hybridization  with vgr-1 
cDNA  and  stringent washing. The 
positions of 28S and 18S ribosomal 
RNA are marked. (B) Western blot 
analysis of conditioned media from 
CHO (lanes I and 3) and CHO-vgr-I 
cells (lanes 2 and 4) incubated with 
either antisera  directed  against the 
vgr-1 precursor segment (lanes I and 
2) or mature vgr-I protein (lanes 3 
and 4). Protein standards are noted. 
(C) Immunostaining of (/) CHO and 
(2)  CHO-vgr-I transfectants  with 
affinity-purified vgr-1 antibody  di- 
rected against the precursor portion 
of the molecule. Bar, 100 sm. 
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Figure 4. Growth rate of CHO vs CHO-vgr-1 transfectants. Cells were grown in either 10% fetal calf serum (A) or in insulin, transferrin, 
and selenium (/3). The growth of CHO cells is represented by the full line with open symbols, and CHO-vgr-1 ceils are noted by the dashed 
line with closed symbols. Three independent plates were grown for each cell type under each condition at each time point, and each plate 
was counted individually three times and then averaged. Each point on the graph represents the average of these readings, with standard 
deviation as noted by the error bars. 
Gitelman et al. Vgr-I Induces Endochondral Bone Formation In Vivo  1601 died from nonspecific causes before visible tumor growth oc- 
curred. After 2 wk, tumors were visible in all mice injected 
with either cell line. In concordance with the in vitro growth 
rate studies, the tumors produced by the parental cells grew 
faster than those from the vgr-l-transfected CHO cells (data 
not shown). After 1 mo, or by the time the tumors reached 
4 cm in largest diameter, the animals were killed and autop- 
sies were performed. 
The tumors produced by both cell types were well local- 
ized and encapsulated.  However,  the tumors had striking 
differences in gross morphology (Fig. 5). The parental cells 
produced tumors with a convoluted surface, and they were 
hemorrhagic, necrotic, and friable (Fig. 5 A). In contrast, the 
CHO-vgr-1  tumors did not have a  significant hemorrhagic 
component, had a  smooth surface, and were quite dense, 
firm, and fibrotic (Fig. 5 B). 
Histological examination of these tumors  further high- 
lighted the differences noted in the gross morphology. He- 
matoxylin and eosin staining of the CHO tumors showed 
nests of tumor cells surrounded by necrotic debris, as well 
as red and white blood cells (Fig. 6 A). Similar nests of tu- 
mor cells were also seen in the CHO-vgr-1 tumors, but there 
were no significant areas of necrosis. Moreover, the tumor 
ceils were encompassed by regions of fibrosis, with signifi- 
cant expansion of surrounding connective tissue (Fig. 6 B). 
The tumors induced by the CHO-vgr-1 cells appeared to con- 
tain a well-developed vasculature, which in turn supported 
the growth and development of an organized tissue mass. 
Bone and Cartilage Formation in rgr-1 Expressing 
CHO Tumors 
Further  histological  examination  of  hematoxylin-eosin- 
stained tissue sections from CHO-vgr-1  revealed regions of 
cartilage and bone tissue within portions of the mesenchyme 
in and around the tumors, accounting for ~20% of the tumor 
mass (Fig. 6 C). These areas contained varying amounts of 
cartilage and bone, with some consisting solely of cartilage, 
others containing a mixture of both cartilage and bone, and 
finally, areas corresponding solely to bone. No bone and car- 
tilage tissue was observed in any of the tumors derived from 
the parental CHO cells. 
Figure 5. Gross morphology of  tumors produced by CHO or CHO- 
vgr-1 cells.  (A)  A  CHO  tumor,  with  convoluted surface and 
significant  hemorrhage, was friable and necrotic. (B) A CHO-vgr-1 
tumor, with smooth surface  and only limited hemorrhage, was firm, 
dense, and fibrotic. Scale bar indicates the size of the tumors. 
To further characterize these areas of bone and cartilage 
formation,  we  performed  several  histochemical  and  im- 
munohistochemical staining procedures. In Fig. 7, the tumor 
sections  were  stained  with  Alcian blue,  which  binds  to 
mucopolysaccharides found in cartilage.  The CHO tumor 
sections did not stain with Alcian blue, but only with the 
counterstain, whereas the CHO-vgr-1  tumors contained ex- 
tensive regions of blue staining (Fig. 7, A and B). At higher 
magnification,  these  areas  appeared  morphologically  as 
chondrocytes or hypertrophic chondrocytes (Fig. 7 C). An 
adjacent section was stained by the von Kossa method, and 
some of these same areas stained black, indicating regions 
of mineralization. Thus, such areas contained hypertrophic 
cartilage that had mineralized; if this tumor had been in- 
cubated longer in vivo, then this area would presumably have 
been replaced by bone. 
To confirm areas of bone formation within the CHO-vgr-1 
tumors, we analyzed different sections using the yon Kossa 
and trichrome staining methods. As shown in Fig. 8, CHO- 
vgr-1 tumors, but not tumors derived from the parental CHO 
cells, had areas that stained positively in regions that ap- 
peared  morphologically as  trabecular  bone.  At  a  higher 
magnification, we noted the presence of osteoblasts, osteo- 
cytes, and osteoclasts within such areas of trabeeular bone. 
The regions of cartilage and bone were further defined 
with immunohistochemical analyses for collagen II, which 
is specifically deposited in cartilage, and for collagen I and 
osteocalcin, proteins associated with bone. Portions of the 
CHO-vgr-1  tumor stained specifically with the collagen II 
antibody, with such staining apparent in cartilage matrix,but 
not in areas of apparent bone formation (Fig. 9 A). No colla- 
gen II staining was detected in the CHO tumors. Other areas 
that appeared histologically as bone were stained with anti- 
bodies for both collagen I and osteocalcin (Fig. 9, B and C). 
No such dual collagen I and osteocalcin staining was seen 
in any region of the CHO tumors. Collagen I staining was 
not confined to bone in the CHO-vgr-1 tumors, but was also 
noted within areas of surrounding connective tissue; wide- 
spread staining was also noted within the CHO tumors in 
regions of necrotic debris. Finally, CHO-vgr-1  tumors also 
had regions that stained with all three antibodies, indicative 
of cartilage adjacent to bone tissue (Fig. 9 D). Collectively, 
these findings suggest that there had been a recapitulation of 
endochondral bone formation within these tumors, in which 
a  cartilage  template  formed  initially and  was  eventually 
replaced by bone. 
We postulated that the vgr-1 secreted by the transfected 
CHO cells had induced mesenchymal cells of  the host animal 
to  differentiate into  bone  and  cartilage.  Indeed,  mesen- 
chymal cells are known to differentiate into chondroblasts 
and  osteoblasts,  whereas  CHO  cells  are  not  known  to 
differentiate.  To  prove  this  hypothesis,  we  designed  a 
riboprobe  for in situ hybridization to distinguish injected 
CHO cells from host mouse cells. Although both the host 
and  transfected  CHO  cells  expressed  endogenous  dhfr 
mRNA, the CHO cells also overexpressed an additional dhfr 
mRNA derived from the transfected expression vector (45). 
This latter transcript contained a unique 3' untranslated re- 
gion derived from the hepatitis B surface antigen gene. This 
region served as a riboprobe to specifically identify CHO 
cells within the tumor samples. As seen in Fig. 10 A, the anti- 
sense riboprobe hybridized intensely to the nests of CHO- 
The Journal of Cell Biology, Volume 126,  1994  1602 Figure 6. Haematoxylin and eosin stain- 
ing of tumors. (A) Section from a CHO 
tumor, showing areas of darker stained 
tumor  cells  with  surrounding  hemor- 
rhage  (orange)  and  necrosis  (lighter 
stained pink areas).  Bar, 200/zm.  (B) 
Section from a CHO-vgr-1 tumor, show- 
ing two regions of darker stained tumor 
cells separated by connective tissue. (C) 
Section  of CHO-vgr-1  tumor  showing 
areas of cartilage (upper left corner of 
figure,  large arrow)  and bone (smaller 
arrows).  Magnification for A  and B  is 
xl0, and C is  ×20. 
Gitelman et al. Vgr-1 Induces Endochondral Bone Formation In Vivo  1603 Figure 7. Regions of cartilage within the CHO-vgr-1 tumors. (A) CHO tumor stained with Alcian blue and nuclear fast red counterstain, 
with only the counterstain visualized. CHO cells are present in the upper left corner of the figure, with surrounding necrotic debris and 
red blood cells (tan). Image is seen at ×10. Bar, 200 #tin. (B) ×10 view of CHO-vgr-1 tumor stained with Alcian blue, with marked areas 
of  intense blue staining the matrix surrounding chondrocytes. (C) ×20 view of  the Alcian blue staining region shown in R Cell morphology 
corresponds to chondrocytes and hypertrophic cbondrocytes. (D) yon Kossa stain of an adjacent section, with black areas corresponding 
to mineralization of some portions of the cartilage. 
vgrol tumor cells, but did not react with the cells in the carti- 
lage and bone tissue and surrounding mesenchyme at the 
tumor periphery. Therefore, the cells within these tissues 
must have arisen from mesenchymal cells of the host animal 
that had been incorporated into the tumor. A low, uniform 
background of nonspecific hybridization was seen using the 
sense strand probe as a negative control (Fig. 10, C and D). 
This conclusion was further strengthened by the positive im- 
munostaining for osteocalcin (Fig. 9). This antibody recog- 
nizes only mouse but not hamster osteocalcin, confirming 
that the bone tissue must have originated from mouse. 
Discussion 
Little is currently known about the function of a distinct sub- 
group of the TGF-~ superfamily consisting of BMP-5, vgr-1/ 
BMP-6, OP-1/BMP-7,  and OP-2. We have focused on vgr-1/ 
BMP-6 as a prototype member of this subgroup. The previ- 
ous finding that vgr-1 mRNA is the only TGF-B superfamily 
member localized to hypertrophic cartilage suggests that it 
may play a pivotal role in the transition of cartilage to bone 
during endochondral bone formation. We report here the 
generation of vgr-l-specific antibodies and the subsequent 
immunohistocbemical localiz~ttion of vgr-1 protein to hyper- 
trophic cartilage.  Furthermore, we produced stably trans- 
fected CHO cells expressing recombinant vgr-1  protein at 
high levels. Finally, we injected the vgr-l-expressing CHO 
cells into mice to evaluate the effects of continuous release 
of vgr-1 in vivo. In contrast to the nontransfected cells, the 
minors formed by vgr-l-expressing cells contained extensive 
areas of fibrosis, with bone and cartilage formation in a pat- 
tern that seemed to mimic endochondral bone formation. 
The Journal of Cell Biology,  Volume  126, 1994  1604 Figure  8.  Regions of  bone 
within the CHO-vgr-1 tumors. 
(A) von Kossa stain of CHO- 
tumor, with only background 
nuclear fast red stain visual- 
ized.  CHO cells  stain  pink, 
and they are visualized in the 
left eentrai portion of the fig- 
ure  surrounded  by  necrotic 
debris  and  red  blood  cells 
(staining tan). (B) von Kossa 
stain  of  CHO-vgr-1  tumor, 
with black areas correspond- 
ing  to  regions  of trabecular 
bone. CHO-vgr-1 cells are the 
pink-stained cells on the left 
side  of the  figure.  (C)  Tri- 
chrome stain of CHO tumor 
with no positive staining, and 
only the Weigert bematoxylin 
counterstain  is  visualized. 
CHO cells are the magenta- 
stained regions on the upper 
portion of the figure. (D) Tri- 
chrome  stain  of CHO-vgr-1 
tumor with intense blue stain- 
ing of trabecular bone. CHO- 
vgr-1 ceils  are  the magenta- 
stained  regions  in the upper 
left and lower left portions of 
the figure. All images are seen 
at  x20. Bar, 100/~m. 
Vgr-1 Expression in Hypertrophic Cartilage 
Previous studies have localized vgr-1  expression in the de- 
veloping mouse using  both in  situ  hybridization and  im- 
munohistochemistry (21, 29, 50). The former studies estab- 
lished the expression of vgr-1 mRNA in the central nervous 
system, suprabasal layer of  the epidermis and other epithelial 
structures, and in hypertrophic cartilage. However, using im- 
munohistochemistry,  vgr-1  protein was  found only in  the 
central nervous system and epithelial structures, but not in 
hypertrophic cartilage,  leading  to  the  suggestion  that  the 
mRNA may not be translated in the latter tissue (50). We 
now report that vgr-1 mRNA is indeed translated into protein 
in hypertophic chondrocytes, as assessed by immunohisto- 
chemical staining using our vgr-1  antibody.  The antibody 
staining is  highly localized in the matrix surrounding the 
hypertrophic chondrocytes. This staining pattern  strongly 
suggests that the secreted vgr-1 has a very limited diffusion 
range and that the hypertrophic cartilage matrix serves as a 
reservoir for this TGF-/~ superfamily member. 
Vgr-1  was  immunolocalized  to  hypertrophic  cartilage 
solely  using  an  antibody  against  the  mature,  carboxy- 
terminal portion of the protein. In contrast, both Wall et al. 
(50) and ourselves were unable to detect protein expression 
in this tissue using an antibody directed against the vgr-1 
precursor segment. The reason for this inability remains un- 
clear.  One possibility is that the precursor region has ac- 
quired an altered conformation, either naturally or as a result 
of the treatment procedure, that renders it inaccessible to the 
antibody. If this were the case, then this modification must 
be different from that in epithelial structures and in the cen- 
tral nervous system, where the vgr-1 precursor antibody was 
used successfully. Alternatively, the vgr-1 precursor segment 
may be proteolytically degraded in hypertrophic cartilage. 
This would resemble the proteolytic activation of TGF-/5'I in 
situ after irradiation, which is accompanied by a strong de- 
crease in  immunostaining  using  a  precursor-specific anti- 
body (2). Such vgr-1 precursor segment degradation could, 
in turn, provide higher accessibility of mature vgr-1 for its 
receptor, as in the case of TGF-B. 
Recombinant Expression of vgr-1 Protein and 
Biological Activity In Vivo 
To evaluate the biological  functions  of murine  vgr-1,  we 
generated  an  efficient expression plasmid  to  overexpress 
recombinant protein. CHO cells stably transfected with this 
vector synthesized and secreted high levels of recombinant 
vgr-1 protein, approximately half of which had undergone 
the predicted proteolytic  cleavage. The transfected cells grew 
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bone and cartilage in CHO- vgr-1 tu- 
mors.  (A)  CHO-vgr-1 tumor  section 
stained with a collagen  II antibody,  iden- 
tifying  areas  of  cartilage formation 
(brown). (B) CHO-vgr-1 tumor section 
stained with a collagen I antibody, iden- 
tifying regions corresponding to bone 
(brown). (C) CHO-vgr-1 tumor section 
stained with  an  osteocalcin antibody, 
identifying  regions corresponding  to 
bone  (brown). (D)  CHO-vgr-1 tumor 
section that contains an area that ap- 
pears morphologically as  bone  (/arge 
arrows), and stained with collagen lI an- 
tibody, identifying  chondrocytes  that are 
adjacent to bone tissue (circular brown 
areas  noted  by  smaller  arrows).  All 
views are  x20. Bar, 100 #m. 
slower than the parental cells, but otherwise exhibited no 
significant differences when characterized in vitro. 
To assay the biological activity of vgr-1 in vivo, we intro- 
duced the CHO-vgr-1  transfectants directly into mice via a 
subcutaneous injection, rather than first purifying recom- 
binant protein from conditioned media of the CHO-vgr-1 
cells. Previous studies have documented that CHO cells form 
localized tumors when injected subcutaneously (13), and we 
reasoned  that the  transfected cells  would act  as  a  depot 
source of vgr-1 by continuously releasing the recombinant 
protein within the tumor. As expected, injection of the CHO- 
vgr-1 stable transfectants in nude mice induced tumor for- 
mation, as did the parental cells. However,  the CHO-vgr-1 
tumors showed a striking increase in surrounding connective 
tissue and exhibited bone  and cartilage formation.  Some 
areas showed only cartilage or trabecular bone; others con- 
tained bone intimately associated with adjacent areas of car- 
tilage, or contained areas of mineralized cartilage.  Taken 
collectively,  these  findings  suggest  recapitulation  of en- 
dochondral bone formation, in which a cartilage template is 
first formed, and is later replaced by mineralized bone. 
Another fundamental difference between the tumors in- 
duced by the CHO cells as opposed to the CHO-vgr-1 trans- 
fectants was that the parental cells produced tumors lacking 
any organized vascular supply.  Thus, overgrowth of these 
cells  resulted  in  hemorrhagic,  necrotic  debris,  and  the 
tumors were unable to support development of an organized 
tissue mass. By contrast, the CHO-vgr-1 cells formed tumors 
with a  well-delineated vascular supply,  and thereby sup- 
ported development of well-organized tumor masses, with 
profusion of connective tissue and differentiation  of cartilage 
and bone. During endochondral bone formation, angiogene- 
sis in hypertrophic cartilage is critical for mineralization and 
subsequent bone formation. The endogenous localization of 
vgr-1 to the site of angiogenesis in hypertrophic cartilage 
suggests that this factor may mediate new vessel formation. 
The cellular elements of fibrosis and endochondral bone 
formation within the CHO-vgr-1  tumors did not appear to 
have arisen directly from the CHO cells, but instead from the 
effects of secreted vgr-1 on surrounding host mesenchymal 
cells. Several lines of  evidence support this hypothesis. First, 
the connective tissue, cartilage, and bone did not hybridize 
with a riboprobe that specifically identified the transfected 
CHO cells. Second, CHO cells are not known to differentiate 
The Journal of Cell Biology, Volume 126,  1994  1606 Figure 10.  In situ hybridizations to define CHO cells within the tumors.  (A) Dark-field microscopy of section from a CHO-vgr-1 tumor 
that has been hybridized with an antisense riboprobe directed against the 3' untranslated region of hepatitis B surface antigen. This probe 
corresponds to part of the dhfr transcript  generated from the expression vector transfected into the CHO cells, and most importantly, it 
identifies an mRNA specific to the CHO cells. White grains correspond  to probe that has hybridized to CHO-vgr-1 cells. Note that the 
bone and surrounding mesenchyme lack significant hybridization.  (B) Bright-field view of section shown in A. The darker staining regions 
correspond  to trabecular bone.  (C) Dark-field microscopy  of section from a CHO-vgr-1 tumor that has been hybridized with a sense 
riboprobe to hepatitis B surface antigen, serving as a negative control. A low level of  background hybridization is shown uniformly through- 
out the section.  (D) Bright-field view of the section shown in C. All views are  ×10. Bar, 200 t~m. 
in vitro or in vivo, making it unlikely that the vgr-l-trans- 
fected CHO cells differentiated into osteoblasts or chondro- 
cytes. In fact, the transfected cells exhibited no such differen- 
tiation  when  evaluated  in  vitro.  Third,  the  bone  matrix 
within  the  CHO-vgr-I  tumors  stained  positively  using  a 
monoclonal  antibody  specific  for  mouse  osteocalcin  that 
does not cross-react with rat or hamster osteocalcin, further 
substantiating our conclusion that the ectopic bone did not 
originate  from hamster  cells.  Finally,  conditioned  media 
from CHO-vgr-1 cells, but not from CHO cells, also induced 
ectopic bone formation when injected intramuscularly (Kirk, 
M.,  and S.  E.  Gitelman, unpublished results). 
Vgr-1 secreted by the CHO-vgr-1 tumors appeared to have 
acted only locally within these animals. We have not devel- 
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not formally tested if these animals contained significant  cir- 
culating levels of  this factor. However, analysis of long bones 
near the site of the tumor showed no changes as compared 
to those of the control animals, and extensive autopsies re- 
vealed no significant changes in any other major organs. 
Possible Mechanisms of Vgr-1 Action 
Our findings indicate that recombinant vgr-1 protein was 
sufficient  to induce fibrosis and bone and cartilage formation 
in vivo. Yet, the complexity of such an in vivo study makes 
it  difficult to pinpoint the specific primary actions directly 
attributable to vgr-1, as opposed to secondary actions medi- 
ated through other factors. One important function of vgr-1, 
at least in the context of this study, may be as a chemoattrac- 
tant to  bring  various  cell types to  the  tumor,  including 
mesenchymal precursors. Alternatively, vgr-1 may act as a 
mitogen to increase the number of various host cells already 
present in or near the tumor. In fact, several other members 
of the TGF-/~ superfamily can serve as chemoattractants or 
mitogens for a variety of cell types, including mesenchymal 
cells, fibroblasts, osteoblasts, neutrophils, monocytes, epi- 
thelial cells, and endothelial cells (for examples, see refer- 
ences 19, 39, 42, 58). The most widely studied factor from 
this standpoint has been TGF-/31. Injection of recombinant 
TGF-/31  into  newborn  mice  and  chicken  chorioallantoic 
membrane  induces  a  granulation  tissue  response,  with 
inflammation,  fibrosis,  and  angiogenesis  (42,  58).  The 
hypercellular lesions in the chicken study resulted not from 
cellular  proliferation,  but  from  enhanced  cell  migration 
through chemotaxis (58).  Only limited studies have been 
conducted  with  the  BMPs,  with  BMP-3  and  BMP-4 
chemotactic for monocytes in vitro (9). Further studies are 
needed to determine if  vgr-1 also serves as a chemoattractant 
and/or mitogen, and if  vgr-l's actions in this regard are distin- 
guishable from that of other members of the TGF-/~ super- 
family. Vgr-1 does not alter the growth rate of  two pluripotent 
mesenchymal cell lines in vitro, suggesting that it may not 
function as a mitogen in vivo (Gitelman, S. E., J. Q. Ye, and 
R. Derynck, unpublished results). 
The influx of additional host cells into the tumor site adds 
another layer of  complexity in characterizing the primary ac- 
tions of vgr-1. Each of these cell types may release additional 
factors into the tumor area, such as other TGF-/3 superfamily 
members,  local growth factors, cytokines, or various ex- 
tracellular matrix proteins. Vgr-1 may act in a paracrine fash- 
ion to stimulate production and release of such factors from 
these neighboring host cells, and may also act in concert with 
these factors to induce the fihrotic changes and endochondral 
bone formation noted within the CHO-vgr-1  tumors. 
Role of TGF-[3 Superfamily in Endochondral 
Bone Formation 
Several members of the TGF-/3 superfamily have now been 
shown to induce endocbondral bone formation when in- 
jected in vivo.  TGF-/31 and TGF-/32 induce endochondral 
bone formation when introduced subperiosteally or at a frac- 
ture site, but not at a site that is not anatomically connected 
to bone (4, 23, 32, 35). In contrast, BMP-2, -3, -4, -7, and 
now vgr-1 have the ability to induce ectopic bone formation 
when injected intramuscularly or subcutaneously (17, 28, 43, 
51, 54). Such findings suggest that these BMPs may act on 
a less differentiated  mesenchymal  precursor than TGF-~ dur- 
ing endochondral bone formation. The findings also imply 
functional redundancy among these factors, yet specificity 
appears to reside in the spatially and temporally distinctive 
patterns of  their expression (for an example, see reference 31). 
In all other studies, a recombinant factor has been intro- 
duced in vivo as a purified protein delivered within an inert 
carrier. Our study is the first to have been conducted with 
direct  injection  of CHO  cells  that  continuously release 
recombinant protein.  As  a  result,  comparison  of vgr-rs 
potency with that of the other TGF-/~ related factors is not 
yet possible,  and awaits  purification of recombinant vgr-1 
from conditioned media. 
Definition of the specific role of individual TGF-/~ super- 
family members  in  endochondral bone  formation awaits 
more refined studies, both in vitro and in vivo. The present 
study entailed overexpression of  vgr-1 in an ectopic location, 
and demonstrated that vgr-1 had the ability to initiate mesen- 
chymal differentiation  along the endochondral bone pathway. 
To further define the function of this factor during normal 
bone  and cartilage development,  it will be  important to 
manipulate the expression of vgr-1 and its receptor within 
hypertrophic cartilage,  vgr-rs endogenous site of production. 
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